N

Nanjing Vazyme Biotech Co Ltd
SSE:688105

Watchlist Manager
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Watchlist
Price: 23.5 CNY -6.67% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Nanjing Vazyme Biotech Co Ltd?
Write Note

Relative Value

The Relative Value of one Nanjing Vazyme Biotech Co Ltd stock under the Base Case scenario is 35.64 CNY. Compared to the current market price of 23.5 CNY, Nanjing Vazyme Biotech Co Ltd is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
35.64 CNY
Undervaluation 34%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
47
vs Industry
57
Median 3Y
7.1
Median 5Y
7.1
Industry
7.7
Forward
5.8
vs History
0
vs Industry
8
Median 3Y
36.3
Median 5Y
36.3
Industry
22.7
Forward
93.9
vs History
7
vs Industry
4
Median 3Y
57.8
Median 5Y
57.8
Industry
21.6
vs History
vs Industry
9
Median 3Y
-10.1
Median 5Y
-10.1
Industry
25.2
vs History
71
vs Industry
44
Median 3Y
3.3
Median 5Y
3.3
Industry
2.5
vs History
50
vs Industry
55
Median 3Y
5.8
Median 5Y
5.8
Industry
7.7
Forward
4.6
vs History
52
vs Industry
48
Median 3Y
8.6
Median 5Y
8.6
Industry
9
vs History
vs Industry
10
Median 3Y
11.1
Median 5Y
11.1
Industry
4.2
Forward
23.4
vs History
vs Industry
9
Median 3Y
11.1
Median 5Y
11.1
Industry
4.1
Forward
36
vs History
7
vs Industry
5
Median 3Y
50.4
Median 5Y
50.4
Industry
5.7
vs History
0
vs Industry
0
Median 3Y
-66
Median 5Y
-66
Industry
3.6
vs History
73
vs Industry
41
Median 3Y
5.3
Median 5Y
5.3
Industry
4.6

Multiples Across Competitors

Competitors Multiples
Nanjing Vazyme Biotech Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Nanjing Vazyme Biotech Co Ltd
SSE:688105
9.3B CNY 6.6 393.8 -111 -111
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
CN
N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Average P/E: 239.2
393.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Average EV/EBITDA: 17.2
Negative Multiple: -111
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
CN
N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Average EV/EBIT: 22.5
Negative Multiple: -111
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top